Precisely tuned inhibition of HIF prolyl hydroxylases is key for cardioprotection after ischemia.

Jatho, Aline; Zieseniss, Anke; Brechtel-Curth, Katja; Yamamoto, Atsushi; Coleman, Mathew L; Leon, Ana M Vergel; Biggs, Daniel; Davies, Ben; Pugh, Chris W; Ratcliffe, Peter J; Katschinski, Dörthe M

CIRCRESAHA.120.318216 (2).pdf (1.32 MB)

Precisely tuned inhibition of HIF prolyl hydroxylases is key for cardioprotection after ischemia.

journal contribution

posted on 2021-04-27, 08:52 authored by Aline Jatho, Anke Zieseniss, Katja Brechtel-Curth, Atsushi Yamamoto, Mathew L Coleman, Ana M Vergel Leon, Daniel Biggs, Ben Davies, Chris W Pugh, Peter J Ratcliffe, Dörthe M Katschinski

No description supplied

Funding

Crick (Grant ID: 10501, Grant title: Ratcliffe FC001501)

History

Publisher DOI

https://doi.org/10.1161/CIRCRESAHA.120.318216

Usage metrics

The Francis Crick Institute

Keywords

Prolyl Hydroxylase domain enzyme doxycycline heart failure incidence myocardial infarction prolyl hydroxylase Ratcliffe FC001501 1102 Cardiorespiratory Medicine and Haematology 1103 Clinical Sciences Cardiovascular System & Hematology

Licence

CC BY 4.0

Precisely tuned inhibition of HIF prolyl hydroxylases is key for cardioprotection after ischemia.

Funding

Crick (Grant ID: 10501, Grant title: Ratcliffe FC001501)

History

Publisher DOI

Usage metrics

Categories

Keywords

Licence

Exports